Boston Scientific Corporation
300 Boston Scientific Way
Tel: (800) 876-9960
1538 articles with Boston Scientific Corporation
A roundup of which pharma and biotech companies are grabbing cash before the 2020 calendar closes.
Boston Scientific Corporation announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, to sell its BTG Specialty Pharmaceuticals business for $800 million in cash.
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2020 Evercore ISI HealthCONx Conference on December 1.
Boston Scientific Announces LOTUS Edge™ Aortic Valve System Voluntary Recall and Product Discontinuation
Boston Scientific Corporation has announced it has initiated a global, voluntary recall of all unused inventory of the LOTUS Edge™ Aortic Valve System due to complexities associated with the product delivery system.
On November 12, 2020, Meghan Scanlon, senior vice president and president, Urology and Pelvic Health, and Susie Lisa, vice president, Investor Relations, will participate in a 40-minute question-and-answer session with the host analyst at the 29th Annual Credit Suisse Virtual Healthcare Conference.
Company provides physicians with first portfolio comprised of drug-eluting stent and drug-coated balloon for the treatment of patients with peripheral artery disease
Boston Scientific Initiates Trial to Evaluate WATCHMAN FLX™ Left Atrial Appendage Closure Device as First-Line Treatment for People at Risk of Stroke
Trial to study next-generation device as treatment alternative to NOACs for broader population of patients with non-valvular atrial fibrillation
Boston Scientific Corporation generated sales of $2.659 billion during the third quarter of 2020.
Boston Scientific Announces Transcatheter Cardiovascular Therapeutics 2020 Investor Update and Conference Call Discussing Third Quarter 2020 Results
Boston Scientific Corporation (NYSE: BSX) will webcast an investor update at the virtual 2020 Transcatheter Cardiovascular Therapeutics (TCT) on Thursday, October 15 from 1:00 – 2:00 p.m. EDT . Joe Fitzgerald , executive vice president and president, Interventional Cardiology; Michael Jaff , D.O., vice president and chief m
Boston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems
Next-generation Valve Designed to Reduce Paravalvular Leaking, Improve Procedural Efficiency and Treat More Patients with Expanded Indication over Prior Version
Boston Scientific Announces Expanded Investment and Exclusive Acquisition Option Agreement with Farapulse, Inc.
Boston Scientific Corporation announced it has signed an investment agreement with an exclusive option to acquire Farapulse, Inc., a privately-held company developing a pulsed field ablation system for the treatment of atrial fibrillation and other cardiac arrhythmias.
Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Vercise Genus™ Deep Brain Stimulation (DBS) System in Europe
Boston Scientific announced that the U.S. Centers for Medicare and Medicaid Services granted a New Technology Add-on Payment for the Eluvia™ Drug-Eluting Vascular Stent System as part of the 2021 Inpatient Prospective Payment System.
Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences. On September 9, 2020 , Mike Mahoney , chairman and chief executive officer, and Susie
BioTelemetry, Inc., the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced a sales agent agreement with Boston Scientific, a global medical technology leader.
Boston Scientific Corporation generated sales of $2.003 billion during the second quarter of 2020.
Boston Scientific Receives FDA Approval for Next-Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device
Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device.
PainTEQ, a leading medical device innovator, announced the appointment of Michael Enxing, Chief Commercial Officer of Boston Scientific Corporation, Neuromodulation Division.
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2020 on Wednesday, July 29, 2020 at 8:00 a.m. EDT.